Similar articles for PMID: 11718433

Year	Number of Results
1997	2
1998	4
1999	2
2000	5
2001	16
2002	17
2003	8
2004	16
2005	17
2006	15
2007	14
2008	12
2009	15
2010	9
2011	10
2012	10
2013	7
2014	3
2015	1
2016	1
2018	2
2019	4
2020	1
2021	2
2022	4

1

Role of alendronate and risedronate in preventing and treating osteoporosis.

Peters ML, Leonard M, Licata AA. Peters ML, et al. Cleve Clin J Med. 2001 Nov;68(11):945-51. doi: 10.3949/ccjm.68.11.945. Cleve Clin J Med. 2001. PMID: 11718433 Free article. Review.

2

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG. Umland EM, et al. Clin Ther. 2001 Sep;23(9):1409-21. doi: 10.1016/s0149-2918(01)80116-8. Clin Ther. 2001. PMID: 11589256 Review.

3

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators. Rosen CJ, et al. J Bone Miner Res. 2005 Jan;20(1):141-51. doi: 10.1359/JBMR.040920. Epub 2004 Sep 29. J Bone Miner Res. 2005. PMID: 15619680 Free article. Clinical Trial.

4

Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.

Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Expert Opin Pharmacother. 2007 Nov;8(16):2743-56. doi: 10.1517/14656566.8.16.2743. Expert Opin Pharmacother. 2007. PMID: 17956196 Review.

5

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276. Curr Med Res Opin. 2006. PMID: 16709313 Review.

6

Bisphosphonates for osteoporosis.

[No authors listed] [No authors listed] Drug Ther Bull. 2001 Sep;39(9):68-72. doi: 10.1136/dtb.2001.39968. Drug Ther Bull. 2001. PMID: 11586803 Review.

7

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators. Sebba AI, et al. Curr Med Res Opin. 2004 Dec;20(12):2031-41. doi: 10.1185/030079904x16768. Curr Med Res Opin. 2004. PMID: 15706659 Clinical Trial.

8

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.

Ringe JD, Möller G. Ringe JD, et al. Rheumatol Int. 2009 Dec;30(2):213-21. doi: 10.1007/s00296-009-0940-5. Rheumatol Int. 2009. PMID: 19430791

9

Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.

Emkey R. Emkey R. MedGenMed. 2004 Jul 19;6(3):6. MedGenMed. 2004. PMID: 15520628 Free PMC article. Review.

10

Gastroenterologists and choosing the right bisphosphonate.

Leder BZ, Kronenberg HM. Leder BZ, et al. Gastroenterology. 2000 Sep;119(3):866-9. doi: 10.1053/gast.2000.17841. Gastroenterology. 2000. PMID: 10982780 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed